Navigation Links
Boston Healthcare Associates Roundtable Explores Challenges and Opportunities Surrounding the Value of Big Data within the Life Sciences
Date:5/24/2012

BOSTON, May 24, 2012 /PRNewswire-iReach/ -- Boston Healthcare Associates hosted a roundtable May 16th to discuss the unique challenges and opportunities surrounding the growing volume of big data in the life sciences and how best to utilize its full potential. "Big data" being defined as large sets of data whose size exceeds conventional abilities for effective capture, storage, and analysis.

The increasing volume of life science and health care data offers exciting opportunities for innovators, manufacturers, stakeholders, providers, and patients - but it also poses new challenges. The rising torrent of big data is currently revolutionary in its volume, variety, and potential value. However, the rapid expansion of data, by people and machines, as well as a need for new resources and structures for storage and interpretation, is adding more and more complexity to the task of trying to effectively aggregate and leverage information into actionable insights.   

The roundtable discussed these issues as well as the emerging importance of big data and its potential implications on innovation. Several questions were addressed including: What is unique about big data within the life sciences? Who should have access and control? How should we address patient consent? Will big data drive change in policy/regulation, and ultimately science? What type of investments and resources are needed? What new insights will be drawn? And how quickly will those insights drive real-time decision-making?

"We've entered an era of information explosion in which our capacity to generate data is exceeding our ability to store, process, and use it," said Andrew Ferrara, CEO of Boston Healthcare Associates. "Aggregating and processing this data into meaningful information is key to driving better decisions and swifter outcomes in innovation - translating to better care for patients."

Today's roundtable included a cross-disciplinary group of life science leaders, all working at the forefront of innovation:

  • Andrew Ferrara, CEO, Boston Healthcare
  • Christopher Twardowski, Director Client Services, Boston Healthcare
  • Andrew Tarab, Director Health Economics, Boston Healthcare
  • Dr. Ulrich Goldmann, Senior Vice President, Global Medical Operations, Genzyme, a Sanofi company
  • Michael Braxenthaler, President of Pistoia Alliance; Strategic Alliances, Pharma Research & Early Development Informatics, Roche
  • Dr. Jens Hoefkens, Head of Genedata Expressionist Unit, Genedata
  • Christopher McClure, Business Development & Account Management, Genedata
  • Melli Annamalai, Senior Principal Product Manager, Oracle Database Server Technologies
  • Dave Greenwald, Managing Director, Relay Technology Management
  • Richard Dale, Principal, Sigma Partners

A summary of the roundtable meeting discussion is available for download here.

About Boston Healthcare Associates

Boston Healthcare assists emerging and established biopharmaceutical, medical device, and diagnostic companies worldwide in gaining a competitive advantage in the health care marketplace by helping them unlock the value of their innovations. These companies rely on Boston Healthcare to create opportunities, navigate complexity, grow their businesses, and achieve objectives through reimbursement and market access strategy services, health economics and outcomes research, market analytics and pricing strategy, and business development support services. Clients draw on Boston Healthcare's unique approach to gain a real-world edge in a highly competitive health care environment. For more information, visit www.bostonhealthcare.com

Media Contact: Michal Taton Boston Healthcare, 617-912-5119, mtaton@bostonhealthcare.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Boston Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27
2. Annual Drug Discovery Conferences Being Held in Boston MA, Spring 2012
3. Boston College names Thomas Chiles the Deluca Professor of Biology
4. 4 Boston College faculty members named Sloan Research Fellows
5. Boston University researchers develop novel drug delivery system
6. Boston University School of Medicine researchers clarify link between salt and hypertension
7. Boston University School of Medicine professor honored by American College of Nutrition
8. Register now! Boston meeting will showcase latest aging discoveries
9. NIH training grant awarded to Boston University School of Medicine and College of Engineering
10. Join GSA in Boston for the nations premier aging conference
11. BU researchers identify extensive methane leaks under streets of Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: